<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: HLA matching and outcomes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: HLA matching and outcomes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: HLA matching and outcomes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mary Carmelle Philogene, PhD, DABHI</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H758262768"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Following the first successful kidney transplant between identical twin siblings in 1954, the importance of matching for human leukocyte antigens (HLA) in kidney transplantation was demonstrated in studies that showed better graft survival in HLA identical kidney transplants compared with HLA mismatched transplants [<a href="#rid1">1</a>]. Graft survival was superior in sibling pairs having both the same serologically defined HLA antigens and a nonreactive in vitro mixed lymphocyte proliferative response (MLR) when compared with recipients of randomly matched, deceased donors treated with the same immunosuppressive drugs. There was an intermediate level of graft survival in haploidentical parent-to-child or sibling-to-sibling transplants in which one but not both of the haplotypes matched.</p><p>Several databases, representing pooled information from a large number of collaborating centers, have accumulated additional evidence for the importance of HLA matching in kidney transplantation. Although such pooled data may suffer from variations in protocols and undocumented selection factors, the power of univariate analyses becomes compelling when thousands of patients are included. These large databases include the United Network for Organ Sharing (UNOS); the Collaborative Transplant Study (CTS); the Scientific Registry of Transplant Recipients (SRTR); the American Foundation for Donation and Transplantation (AFDT), previously known as the South-Eastern Organ Procurement Foundation (SEOPF); the United Kingdom Transplant Service; Eurotransplant; the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA); and others.</p><p>Despite a decline in HLA matching following improved immunosuppression treatments, transplant agencies in Europe and the United States maintain policies that encourage HLA matching while increasing access to transplantation. European systems assign weights to A, B, C, DR matching, and in the United States, additional scores are allocated to pediatric kidney transplant candidates who are 0-ABDR mismatched with a donor, and 1 to 2 points are allocated to adult kidney transplant candidates who are 0 or 1 DR mismatched with a donor [<a href="#rid2">2,3</a>]. Nevertheless, donor and patient characteristics, geography, equity, and access consideration are factors that contribute more to priority allocation.</p><p>This topic will review HLA matching and its impact on clinical outcomes among kidney transplant recipients. A general overview of HLA typing, sensitization, and crossmatch testing in kidney transplantation is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing"</a>.)</p><p class="headingAnchor" id="H2085030761"><span class="h1">DETERMINATION OF HLA MATCHING</span><span class="headingEndMark"> — </span>Human leukocyte antigen (HLA) matching between potential donors and transplant candidates is determined by comparing their HLA antigens or alleles. In the United States, Canada, and Europe, HLA typing for waitlisted kidney transplant candidates and donors is performed by low- or high-resolution molecular typing, and serologic equivalents for HLA-A, -B, -C, -Bw4, -Bw6, -DRB1, -DR51/52/53, and -DQB antigens are reported for the transplant candidate. HLA-DPB1 is often reported at the allele level. Donors are typed for HLA-A, -B, -C, -Bw4, -Bw6, -DRB1, -DR51/52/53, -DQA1, -DQB1, -DPA1, and -DPB1 antigens, which are then reported for organ sharing (serologic equivalents are reported when applicable); HLA-DPB1 is entered in UNet at the allele level. Online libraries that are routinely vetted are available for appropriate conversion of molecular typing to serologic equivalencies when necessary. A detailed discussion of the methods used for HLA typing is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing", section on 'HLA typing'</a>.)</p><p>When matching a donor to a recipient, an HLA <strong>mismatch</strong> approach to organ allocation, as opposed to an HLA matching approach, maximizes the number of patients considered to be a match with a deceased donor. As an example, HLA-A2 is a common antigen, and homozygosity is frequent. A donor that is homozygous for HLA-A2 (ie, serologic HLA typing is HLA-A2, A2) will be a zero antigen mismatch for a patient who types as HLA-A2, A23; one who types as HLA-A2, A2; or one who types as HLA-A2, A66. By contrast, a donor that is HLA-A2, A23 will be considered a zero antigen mismatch only for the patient typed as HLA-A2, A23 but will be a one-antigen mismatch with the other two recipients. The degree of mismatch between recipient and donor is primarily determined for HLA-A, -B, and -DR antigens because of their higher expression level and high polymorphism. Thus, a <strong>zero antigen mismatch</strong> between a recipient and donor may be defined as the absence of an HLA-A, -B, or -DR antigen in the donor's phenotype that is different from the recipient's HLA-A, -B, and -DR antigens. It is worth noting that HLA typing at the molecular level may further discriminate HLA molecules at the allele level. Thus, a serologically defined zero antigen mismatch does not rule out allele-level mismatches. Conversely, a <strong>six antigen mismatch</strong> indicates that two A, two B, and two DR antigens in the donor's phenotype are different from those of the recipient. In addition to the antigens listed for transplant candidates, HLA-DQA1 and -DPB1 typing for deceased donors is submitted to the organ procurement organization (OPO) to determine whether antibodies in the transplant candidate's serum are directed against any antigens of the donor. In the United States, molecular typing results are submitted as a PDF attachment to UNet, the computer system operated by the United Network for Organ Sharing (UNOS).</p><p>Several studies have shown that HLA matching is a stronger predictor of kidney allograft survival. In a retrospective study of 96,236 deceased-donor kidney transplants between 1995 and 2012, both HLA matching and mismatching were associated with graft survival when analyzed in individual models [<a href="#rid4">4</a>]. However, when analyzed using a combined model that considered both HLA matching and mismatching simultaneously, only the degree of HLA matching was found to be a significant predictor of delayed graft function, one-year acute rejection, and 10-year graft survival. A subsequent study used UNOS data from 1990 to 1999 to evaluate allograft survival in 76,530 kidney transplant recipients (23,914 living-donor allograft recipients and 52,616 deceased-donor allograft recipients) with varying degrees of HLA matching [<a href="#rid5">5</a>]. On adjusted multivariable analysis, more HLA mismatches were associated with lower graft survival beyond 10 years (higher risk of graft loss with 1 versus 6 HLA mismatched antigen). The data continue to show an improvement in allograft survival with fewer HLA mismatches between donor and recipient. Certainly, using HLA matching for allocation limits access to transplantation for recipients from underrepresented groups with rare HLA antigens not present in a primarily White donor pool. (See <a class="local">'Underrepresented groups'</a> below.)</p><p class="headingAnchor" id="H1716312569"><span class="h1">HLA MISMATCHING AND SENSITIZATION</span><span class="headingEndMark"> — </span>The high polymorphism in the human leukocyte antigen (HLA) system results in multiple variations of antigens. Consequently, transplant candidates must often receive an organ from a donor with one of several HLA mismatched antigens. Exposure to an HLA antigen that is non-self can lead to development of antibodies against the mismatched HLA antigen(s). This is known as sensitization. HLA sensitization can result from prior exposures to HLA mismatched antigens through pregnancies, blood transfusions, or previous transplantation. HLA sensitization can also develop following immune activation in patients with ventricular assist devices, infections, following surgical procedures, and possibly after vaccination. (See  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing"</a>.)</p><p>The development of antibodies against HLA antigens can lead to serious complications posttransplantation and present significant hurdles for patients who are relisted for a second transplant. Given that the presence of HLA antibody in a patient's serum constitutes an additional barrier in selecting compatible donors, assays that detect and characterize these antibodies are used to evaluate a patient's immunologic risk prior to donor selection. For a sensitized patient, donors that express HLA antigens against which the patient has preformed antibody should be avoided when possible, and these HLA antigens are reported in UNet as "unacceptable antigens." Accurately defining the anti-HLA antibody profile of a potential transplant candidate is important since this information is used to perform virtual crossmatches. The virtual crossmatch uses the results of the antibody tests along with donor and patient HLA typing to predict a candidate's compatibility with a donor of interest. At the time of transplantation, most centers perform a physical crossmatch by incubating lymphocytes from a potential donor with serum from the transplant candidate in a complement-dependent cytotoxicity (CDC) or flow cytometric crossmatch test. An overview of crossmatch testing in kidney transplantation is presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing", section on 'Assays for antibody screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing", section on 'Assays for crossmatch testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing", section on 'Virtual crossmatch'</a>.)</p><p></p><p class="headingAnchor" id="H3332234049"><span class="h1">HLA FACTORS ASSOCIATED WITH TRANSPLANT OUTCOMES</span></p><p class="headingAnchor" id="H4058635284"><span class="h2">Number of mismatched HLA antigens</span><span class="headingEndMark"> — </span>Data from large registry studies have shown that a higher degree of human leukocyte antigen (HLA) mismatching is associated with worse transplant outcomes. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a United Network for Organ Sharing (UNOS) registry analysis of 189,141 first, adult, kidney-alone transplants performed between January 1, 1987 and December 31, 2013, there was a 13 percent higher risk of graft failure with one HLA mismatch and a 64 percent higher risk with six HLA mismatches, with increasing risk for each level of mismatch [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings were reported in an analysis of the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) that included 8036 living- and deceased-donor kidney transplant recipients between 1998 and 2009 [<a href="#rid7">7</a>]. Compared with zero HLA-antigen mismatch, increasing HLA mismatches were associated with a higher risk of graft failure; there was a 7 percent higher risk of graft failure with one HLA mismatch and a 74 percent higher risk with six HLA mismatches.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 11 cohort studies involving 289,987 adult kidney transplant recipients found that each incremental increase in HLA mismatch was associated with a higher risk of overall graft failure (hazard ratio [HR] 1.06 per mismatch, 95% CI 1.05-1.07) and death-censored graft failure (HR 1.09 per mismatch, 95% CI 1.06-1.12) [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H1740598607"><span class="h2">Relative importance of specific HLA antigens</span><span class="headingEndMark"> — </span>Several studies have demonstrated that mismatches at individual HLA loci do not have equal weight with regards to transplant outcomes.</p><p class="headingAnchor" id="H2684078584"><span class="h3">HLA-A, -B, and -DR</span><span class="headingEndMark"> — </span>Analyses of large transplant registries have consistently shown a strong association between HLA matching, particularly at the HLA-A, -B, and -DR loci, and patient and graft outcomes [<a href="#rid7">7,9,10</a>]. These HLA antigens have the most polymorphisms.</p><p>The initial Collaborative Transplant Study (CTS) analysis showed that the major impact on kidney allograft outcomes came from mismatches for the HLA-DR and -B antigens, with little additional effect from the HLA-A antigens [<a href="#rid11">11,12</a>]. The United Kingdom Transplant Service and Eurotransplant data were somewhat similar, with HLA-DR matching having a much greater effect than HLA-B or -A [<a href="#rid13">13,14</a>]. Another study found that HLA-DR mismatches (and the number of rejection episodes) correlated with poor long-term survival [<a href="#rid15">15</a>].</p><p>Mismatching for HLA-A, -B, and -DR has been associated with a higher risk of HLA sensitization in both adult and pediatric patients who are relisted for a second kidney transplant (see  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing"</a>). As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 15,980 patients from the Scientific Renal Transplant Registry (SRTR) database who were relisted after the loss of a primary kidney transplant, patients with higher HLA-A, -B, and -DR mismatching had a greater likelihood of being newly sensitized at relisting (adjusted odds ratio [OR] 2.60 and 3.84 for one and six mismatches, respectively). Only 10 percent of patients became sensitized after a zero HLA-mismatched transplant, compared with 37 percent of those with increasing HLA mismatches [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 2704 pediatric kidney transplant recipients who were relisted after primary graft failure, an increasing number of HLA-DR mismatches at first transplantation was associated with a higher degree of sensitization [<a href="#rid17">17</a>]. In addition, two HLA-DR mismatches at first transplant were associated with a 20 percent lower likelihood of receiving a second transplant.</p><p></p><p>Prior sensitization against HLA class II antigens has also been associated with an increased risk for major adverse cardiac and cerebrovascular events as well as all-cause mortality in kidney transplant recipients [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H2020350538"><span class="h3">HLA-DQ</span><span class="headingEndMark"> — </span>Although HLA-DQ is not as polymorphic as HLA-A, -B, and -DR, HLA-DQ mismatches have been associated with an increased risk of rejection and allograft loss in kidney transplant recipients [<a href="#rid19">19-21</a>]. Consequently, UNOS has amended its policy, requiring deceased-donor HLA typing to include identification of the HLA-DQ antigens before making any kidney, kidney-pancreas, pancreas, or pancreas islet offers [<a href="#rid22">22</a>]. However, the existing UNOS kidney allocation policy does not include HLA-DQ matching in the algorithms for organ allocation.</p><p>The relative importance of HLA-DQ mismatches is illustrated in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>A study of the ANZDATA registry of kidney recipients transplanted between 2004 and 2012 revealed that, compared with recipients of zero HLA-DQ mismatched kidneys, the adjusted HRs for rejections in recipients who had received one or two HLA-DQ-mismatched kidneys were 1.54 (95% CI 1.08-2.19) and 2.85 (95% CI 1.05-7.75), respectively [<a href="#rid19">19</a>]. HLA-DR was an effect modifier between HLA-DQ mismatches and antibody-mediated rejection (ABMR) such that the association between HLA-DQ mismatches and ABMR was statistically significant among those who received one or two HLA-DR-mismatched kidneys, with adjusted HR of 2.50 (95% CI 1.05-5.94).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of adult kidney transplant recipients from the UNOS database, HLA-DQ mismatches, compared with no HLA-DQ mismatches, were associated with a higher risk of rejection at one year posttransplant in recipients of living- and deceased-donor transplants (adjusted OR 1.14, 95% CI 1.03-1.27, and 1.13, 95% CI 1.03-1.23, respectively) [<a href="#rid20">20</a>]. In addition, compared with no HLA-DQ mismatches, HLA-DQ mismatches were associated with a higher risk of graft loss among recipients of a living-donor transplant (HR 1.18, 95% CI 1.07-1.30) and deceased-donor transplants with cold ischemia time ≤17 hours (HR 1.12, 95% CI 1.02-1.27).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study, the incidence of preformed anti-HLA-DQ antibodies in kidney transplant recipients was 11 percent and increased to 36 percent posttransplantation [<a href="#rid21">21</a>]. In this study, transplant recipients with de novo persistent DQ-only donor-specific antibody (DSA) or de novo DQ plus other DSAs had more acute rejection episodes, increased risk of allograft loss, and a lower five-year allograft survival compared with recipients who did not have DSA.</p><p></p><p>HLA class II mismatches, which include HLA-DQ and -DR, have been found to be a risk factor for the development of de novo DSAs. In one study of 315 consecutive kidney transplants without pretransplant DSA, 47 patients (15 percent) developed de novo DSA at a mean of 4.6 years posttransplant [<a href="#rid23">23</a>]. Independent predictors of de novo DSA included HLA-DR mismatches (OR 5.66) and nonadherence to immunosuppression. Similarly, a second study of 189 nonsensitized, non-HLA-identical patients who received a first-kidney transplant found that HLA-DQ mismatches were an independent risk factor for the development of de novo DSA (HR 3.14, 95% CI 1.24-7.94) [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H2866085007"><span class="h3">HLA-C</span><span class="headingEndMark"> — </span>Few studies have addressed the impact of HLA-C mismatches. One study of 2260 deceased-donor kidney transplant recipients found that mismatching for one or both HLA-C antigens was associated with decreased graft survival among those who were presensitized (panel reactive antibodies [PRA] &gt;10 percent) but not those who were not presensitized [<a href="#rid25">25</a>].</p><p>Forty to 50 percent of kidney transplant recipients may have preformed anti-HLA-C antibodies [<a href="#rid26">26-28</a>]. However, the effect of HLA-C antibodies on allograft outcome is controversial. Some studies have suggested that HLA-C antibodies are associated with the incidence of acute rejection, while others have shown some correlation with allograft loss [<a href="#rid26">26,29,30</a>]. The availability of single-antigen bead (SAB) assays has allowed better detection of antibodies against HLA-C antigens and facilitated studies that examine their effect on transplantation outcome. In a retrospective, single-center study, 608 transplant patients were assessed for DSA as defined by a mean fluorescence intensity (MFI) &gt;500 [<a href="#rid31">31</a>]. Of these patients, 160 (26 percent) had DSA, and 25 (4 percent) had HLA-C antibodies at the time of transplant (day 0). Among the 22 patients with HLA-C antibodies who were available for follow-up, the incidence of ABMR in the first year was 27 percent. The mean MFI among patients with HLA-C antibody who developed ABMR was significantly higher than for patients who did not have ABMR (mean MFI values = 4966 versus 981, respectively), suggesting that patients with high levels of pretransplant HLA-C DSA may be more likely to develop ABMR during the first posttransplant year.</p><p class="headingAnchor" id="H3946644143"><span class="h3">HLA-DP</span><span class="headingEndMark"> — </span>Anti-HLA-DP antibodies are less common than antibodies to HLA-DR and -DQ, occurring in 5 to 14 percent of transplant recipients [<a href="#rid32">32-34</a>]. The frequency of HLA-DP antibodies increases in patients who were previously transplanted, occurring in up to 45 percent of retransplanted subjects [<a href="#rid34">34</a>]. Although some studies have suggested that the presence of HLA-DP antibodies does not reduce allograft survival among recipients of a first transplant [<a href="#rid32">32</a>], other studies have found that HLA-DP antibodies correlate with reduced allograft survival among recipients of a second transplant [<a href="#rid35">35-40</a>].</p><p class="headingAnchor" id="H3669887321"><span class="h2">Repeated mismatched HLA antigens</span><span class="headingEndMark"> — </span>Reexposure to repeated mismatched HLA antigens may trigger reactivation of memory cells and a rebound in DSA immediately posttransplant, leading to earlier graft injury and loss [<a href="#rid41">41-43</a>]. While the presence of repeated mismatched antigens associated with DSA is generally avoided in kidney transplantation, repeat mismatches alone in the absence of circulating DSA may <strong>not </strong>need to be categorically avoided, as this practice may further limit access to transplantation.</p><p>Studies evaluating the impact of repeated mismatched HLA antigens on graft outcomes have yielded mixed results. Although some studies have reported a correlation between repeated mismatches and decreased graft survival [<a href="#rid44">44-47</a>], others have showed no effect on graft outcomes [<a href="#rid48">48-53</a>]. As an example, an analysis of 13,789 recipients of a second kidney transplant between 1995 and 2011, of whom 3868 (28 percent) had one or more repeated mismatches, found no association between the presence of any repeated mismatches (either HLA class I or II) and all-cause or death-censored graft loss [<a href="#rid50">50</a>]. In a subgroup analysis that examined the effect of HLA class I versus class II repeated mismatches, the presence of an HLA class II repeated mismatch was found to be associated with a higher risk of death-censored graft loss but only among patients who were sensitized or underwent a nephrectomy of the first allograft before the second transplant. The better outcomes in this study may have been related to the use of modern-era immunosuppression and more sensitive HLA antibody-detection assays. Because earlier studies evaluating the impact of repeated mismatches used less sensitive methods (ie, complement-dependent cytotoxicity [CDC] crossmatch testing) to test for anti-HLA antibodies, they were less likely to detect low-level antibodies against repeated mismatched antigens. Consequently, this may have led to transplants with repeated mismatched antigens in the presence of undetected antibodies and the resulting negative impact on transplant outcomes. With the use of more sensitive HLA-testing tools in the contemporary study cited above, repeated mismatches against which a patient had already produced donor-specific anti-HLA antibodies would have been avoided and not included in the cohort evaluated.</p><p>In the absence of available assays to detect memory B cells, the clinical characteristics of the patient should be assessed along with information on historical HLA antibody levels when considering a transplant across repeated mismatches.</p><p class="headingAnchor" id="H2956818195"><span class="h2">Exposure to noninherited HLA alleles</span><span class="headingEndMark"> — </span>In utero and while nursing, infants are exposed to maternal antigens that the child has not inherited. There is evidence that such exposure may result in some degree of tolerance. One study of 205 patients evaluated the long-term survival of kidney allografts transplanted from siblings with maternal or paternal HLA alleles not inherited by the recipient [<a href="#rid54">54</a>]. Compared with the kidneys donated from siblings with paternal alleles not inherited by the recipient, a higher incidence of survival was observed among the allografts donated from siblings with noninherited maternal alleles at both 5 and 10 years posttransplantation (86 versus 67 percent and 77 versus 49 percent, respectively). Although many unrecognized factors may be confounding, these results suggest that exposure to donor antigens prior to transplantation may help induce some degree of tolerance [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H2522189995"><span class="h1">STRATEGIES TO OPTIMIZE HLA MATCHING</span><span class="headingEndMark"> — </span>The likelihood of finding a fully human leukocyte antigen (HLA)-matched, unrelated donor for every kidney transplant candidate is low. Alternative strategies have focused on matching based upon structural and conformational similarity between several of the HLA antigens.</p><p class="headingAnchor" id="H2915502604"><span class="h2">HLA epitope matching</span><span class="headingEndMark"> — </span>Antibodies recognize and bind to three-dimensional configurations of amino acids called epitopes  (<a class="graphic graphic_figure graphicRef121595" href="/z/d/graphic/121595.html" rel="external">figure 1</a>). Epitopes consist of approximately 15 to 22 amino acid residues, which may be contiguous in the peptide chain (ie, linear) or, more commonly, brought together by protein folding (ie, conformational) [<a href="#rid56">56-58</a>].</p><p>Each HLA antigen contains a unique set of epitopes (private epitopes) as well as epitopes that are present in other HLA antigens (shared or public epitopes). Previous studies demonstrated that anti-sera used in commercial assays were reactive against more than one HLA antigen. The term cross-reactive epitope groups (CREGs) was used to describe such groups of HLA antigens that shared a common epitope and would be targeted by a common anti-HLA antibody (ie, an anti-HLA antibody that binds to a public epitope will bind to all HLA antigens that share this epitope). Matching for CREGs of HLA antigens was proposed as an alternative to traditional HLA antigen matching for deceased-donor kidney transplantation [<a href="#rid59">59-62</a>]. CREG-based matching was also promoted to improve equity in organ allocation for populations from underrepresented groups who have rarer HLA antigens (see <a class="local">'Underrepresented groups'</a> below). A few early studies reported improved long-term allograft survival when donors were selected based upon CREG-matched groups rather than HLA antigen mismatches [<a href="#rid63">63</a>]. However, a subsequent analysis of 91,917 recipients of a deceased-donor kidney transplant from the Collaborative Transplant Study (CTS) found that matching for CREGs provided no additional benefit over HLA antigen matching for long-term graft outcomes [<a href="#rid64">64</a>].</p><p>Although these mixed results questioned the role of CREG-based matching for donor selection in kidney transplantation, subsequent studies evaluating the effect of mismatches of smaller clusters of amino acids (eplets) on transplant outcomes have renewed interest in HLA epitope matching. (See <a class="local">'HLA eplet-mismatch load'</a> below.)</p><p class="headingAnchor" id="H4164330760"><span class="h2">HLA eplet-mismatch load</span><span class="headingEndMark"> — </span>Eplets are clusters of polymorphic amino acids, discontinuous or linear, that are located on the surface of HLA molecules  (<a class="graphic graphic_figure graphicRef121595" href="/z/d/graphic/121595.html" rel="external">figure 1</a>). They have been characterized based upon molecular modeling of HLA alleles and the comparison among amino acid sequences of HLA alleles. Eplets have been called "functional epitopes" since they include the two to five amino acids that are recognized by anti-HLA antibodies within the larger 15 to 22 amino acids of an HLA epitope. Because eplets, like epitopes, are shared among several HLA antigens, eplet-based matching could be used to identify acceptable matches among different HLA molecules.</p><p>The eplet-mismatch load is determined by counting the number of eplets that are mismatched between a recipient and the potential donor. The number of donor-recipient eplet mismatches can be determined using an available <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.epitopes.net%2Fdownloads.html&amp;token=Mc7565XbopULUo1YtDbTd3dHUvfR91MEXmuOqMIhLUy0aJUFpBmOzrH%2BSvD5cBQj&amp;TOPIC_ID=7355" target="_blank">computer algorithm</a> called the HLAMatchmaker. Several observational studies have shown that a higher number of mismatched eplets is associated with a higher risk of developing donor-specific antibody (DSA) posttransplantation [<a href="#rid65">65-69</a>] and a higher risk of graft loss [<a href="#rid70">70</a>]. Eplet mismatches in HLA-DQ also appear to confer a significant risk for de novo DSA formation, rejection, and graft failure after kidney transplantation [<a href="#rid69">69</a>].</p><p>While eplets identified in HLAMatchmaker were found to correlate with antibody production, one study showed that HLAMatchmaker does not predict which eplets (or amino acid sequences) will elicit a T cell response [<a href="#rid71">71</a>]. The Predicted Indirect Recognizable HLA Epitope (PIRCHE) is a novel HLA epitope matching algorithm that considers epitopes that are recognized by T helper cells as they are presented by recipient HLA molecules to recipient T cells via the indirect pathway for peptide presentation. Several studies have shown a correlation between PIRCHE scores and the subsequent development of de novo DSA. As an example, one study demonstrated that higher numbers of PIRCHE mismatches were associated with an increased risk of rejection episodes and de novo DSA production [<a href="#rid72">72</a>]. Another study showed in a multivariate model that for a 2.7-fold increase in PIRCHE score, the risk of graft failure increased 13 percent [<a href="#rid73">73</a>].</p><p>The use of eplet-mismatch load for organ allocation has been reported in small studies with homogenous populations [<a href="#rid74">74,75</a>]. However, these results are preliminary, and larger studies including more heterogeneous cohorts of transplant patients are needed to validate this approach. Limitations in the use of this approach of epitope matching for donor selection include a better distinction between the use of eplet-mismatch load versus immunogenic eplets and<strong> </strong>the availability of analysis software [<a href="#rid76">76</a>]. (See <a class="local">'Immunogenicity of HLA antigens'</a> below.)</p><p class="headingAnchor" id="H184795691"><span class="h2">Immunogenicity of HLA antigens</span><span class="headingEndMark"> — </span>Not all epitope mismatches result in the development of alloantibody responses. Factors such as the HLA antigens of the patient and conformational structure of the epitope may determine whether exposure to an HLA antigen results in an immune response [<a href="#rid77">77</a>]. Some studies, for example, have shown that the physiochemical properties of amino acids, including hydrophobicity and the electrostatic charges of their side chains, are important determinants of the immunogenicity of an antigen [<a href="#rid68">68,78</a>]. Avoidance of HLA antigens that are known to be more immunogenic, particularly among pediatric transplant candidates, may reduce the incidence of antibody development if retransplantation is required.</p><p class="headingAnchor" id="H1950512260"><span class="h1">HLA MATCHING AND TRANSPLANT OUTCOMES</span></p><p class="headingAnchor" id="H720173939"><span class="h2">Long-term graft survival</span><span class="headingEndMark"> — </span>Most transplants that are lost to acute rejection do so within the first year. Later graft loss is primarily due to "chronic rejection," a disorder that is more difficult to treat with existing immunosuppressive regimens. (See  <a class="medical medical_review" href="/z/d/html/7359.html" rel="external">"Kidney transplantation in adults: Chronic allograft nephropathy"</a>.)</p><p>Multiple analyses have demonstrated that human leukocyte antigen (HLA) matching is associated with improved long-term graft survival [<a href="#rid4">4,79</a>]. In the 2008 annual report of the Scientific Registry of Transplant Recipients (SRTR), the five-year, deceased, nonextended-criteria donor allograft survival for zero versus six HLA-mismatched, deceased-donor kidneys was 75 and 66 percent, respectively [<a href="#rid80">80</a>].</p><p>Long-term graft survival is also best in HLA-identical, particularly living-related, kidneys and worst in randomly matched cadaver kidneys [<a href="#rid79">79,81</a>]. As an example, a report from the same United Network for Organ Sharing (UNOS) database evaluated more than 7600 HLA-matched (ie, no mismatches) and 81,000 HLA-mismatched cadaveric kidney transplants performed between 1987 and 1999 in the United States [<a href="#rid79">79</a>]. HLA-matched transplants had longer allograft half-lives (12.5 versus 8.6 years) and increased 10-year survival (52 versus 37 percent). Similar findings have been reported in subsequent years [<a href="#rid80">80</a>].</p><p>Although several reports have reaffirmed the role of HLA matching in kidney transplantation [<a href="#rid4">4,7,9,11,25,82-84</a>], some studies have challenged the importance of HLA matching [<a href="#rid85">85</a>]. As an example, one study suggested that the importance of HLA matching for allograft survival may have diminished over the last several years, with nonimmunologic factors assuming more relative significance [<a href="#rid85">85</a>]. In this study, the factors underlying allograft survival over the period of 1994 to 1998 were evaluated among over 30,000 transplant recipients of deceased-donor kidneys. With each successive year, ever-increasing degrees of HLA mismatching were required to have a statistically significant adverse effect upon allograft failure. Thus, increased allograft failure was significantly associated with the following: three to six antigen mismatches in 1995, four to six antigen mismatches in 1996, five and six antigen mismatches in 1997, and six antigen mismatches in 1998. By comparison, peak panel reactive antibodies (PRA); donor age, sex, and cause of death; cold ischemia time; and donor and recipient body size retained their relative importance for allograft survival over this period. The administration of increasingly better immunosuppressive regimens during this period may in part underlie these observations.</p><p>Despite these conflicting reports, the weight of overall evidence suggests that HLA matching still has a significant impact on allograft survival. The main effect can be observed between a zero antigen mismatch versus a six antigen mismatch. Based upon the 2008 Organ Procurement Transplant Network/Scientific Registry of Transplant Recipient (OPTN/SRTR) database, for example, allograft survival at five years for those with zero or six total mismatches was [<a href="#rid86">86</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Eighty-eight and 79 percent for living-donor kidneys, respectively</p><p class="bulletIndent1"><span class="glyph">●</span>Seventy-five and 66 percent for deceased, nonextended-criteria donor kidneys, respectively</p><p class="bulletIndent1"><span class="glyph">●</span>Sixty and 55 percent for deceased, extended-criteria donor kidneys, respectively</p><p></p><p>The improved long-term graft survival observed in well-matched HLA grafts may be less apparent in transplant recipients with a primary glomerular disease. In one report of 60 patients in whom an HLA-identical, living-related-donor transplant had been performed, allograft survival was correlated with the original kidney disorder [<a href="#rid87">87</a>]. Among the 33 patients with an underlying glomerulonephritis, the 5-, 10-, and 20-year graft survival was 88, 70, and 63 percent, respectively; by comparison, no case of graft loss was observed among the remaining patients with nonglomerular kidney disease. In this study, recurrent disease appeared to be the principal cause of graft loss.</p><p class="headingAnchor" id="H249470742"><span class="h2">Patient survival compared with waiting list</span><span class="headingEndMark"> — </span>Although graft survival of HLA-mismatched kidneys is reduced compared with HLA-matched kidneys, patient survival of highly sensitized recipients of HLA-mismatched kidneys is higher when compared with highly sensitized transplant candidates who remain on the waiting list and are undergoing dialysis. This was suggested by a multicenter study that compared survival of 1025 recipients of HLA-incompatible, living-donor kidneys with matched, waitlisted controls who either never received a kidney or who eventually received an HLA-compatible, deceased-donor kidney [<a href="#rid88">88</a>]. HLA-incompatible recipients were defined as those who were transplanted across an HLA barrier and underwent desensitization protocols prior to transplantation to reduce levels of donor-specific anti-HLA antibodies (DSAs) [<a href="#rid89">89</a>]. For each recipient of a mismatched kidney, five matched, waitlisted controls who never received a transplant and five matched, waitlisted controls who eventually received a deceased-donor kidney were drawn from the SRTR waiting list. The desensitization protocol employed was defined by individual centers.</p><p>Compared with candidates on the waiting list who never received a kidney, survival was higher among recipients of HLA-mismatched kidneys at one year (89.6 versus 95 percent), three years (72.7 versus 91.7), five years (59.2 versus 86 percent), and eight years (43.9 versus 76.5 percent). Even compared with waitlisted candidates who eventually received a deceased-donor kidney, survival was higher among recipients of HLA-mismatched kidneys at one year (94 versus 95 percent), three years (83.6 versus 91.7 percent), five years, (74.4 versus 86 percent), and eight years (43.9 versus 76.5 percent).</p><p>Importantly, this survival benefit was observed at all levels of DSAs:</p><p class="bulletIndent1"><span class="glyph">●</span>At mild DSA levels (defined by a positive single antigen bead assay but negative flow cytometry crossmatch, n = 185), compared with waitlisted candidates who never received a kidney and compared with candidates who eventually received a deceased-donor kidney, survival was higher among HLA-incompatible recipients at one year (90.6 versus 94 versus 98.4 percent, respectively), three years (76.3 versus 85.2 versus 95.1 percent, respectively), five years (61.9 versus 74.6 versus 91.2 percent, respectively), and eight years (47.1 versus 65 versus 89.2 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At moderate DSA levels (defined by positive flow cytometric crossmatch but negative cytotoxic crossmatch, n = 536), compared with waitlisted candidates who never received a kidney and candidates who eventually received a deceased-donor kidney, survival was higher among HLA-incompatible recipients at one year (89.7 versus 94.5 versus 96.1 percent, respectively), three years (72.1 versus 83.8 versus 93.3 percent, respectively), five years (58.4 versus 74.9 versus 87.1 percent, respectively), and eight years (43 versus 63.3 versus 76.3 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with a positive cytotoxic crossmatch indicating a high DSA level (n = 304), survival at one year was similar among HLA-mismatched recipients (91.1 percent) compared with both control groups (93 and 88.9 percent). At three, five, and eight years, however, compared with waitlisted candidates who never received a kidney and candidates who eventually received a deceased-donor kidney, survival was higher among HLA-incompatible recipients at three years (71.8 versus 82.2 versus 86.8 percent, respectively), five years (58.8 versus 73.2 versus 80.9 percent, respectively), and eight years (43.7 versus 61.5 versus 71 percent, respectively).</p><p></p><p>These data suggest that transplantation of an HLA-incompatible kidney confers a survival benefit compared with being waitlisted and never receiving a kidney and even compared with being waitlisted and eventually receiving a compatible, deceased-donor kidney. In this study, the survival benefit persisted despite the presence of high DSA levels and was independent of the desensitization protocol utilized. The comparator group was drawn from all patients on the waiting list rather than just active patients who would be considered suitable for transplantation. Drawing the matched controls from the entire waiting list may have overestimated the apparent benefit of transplantation of an HLA-incompatible kidney. Approximately one-third of patients on the waiting list are not active, and most are inactive because of health issues.</p><p class="headingAnchor" id="H1470859131"><span class="h2">Acute rejection</span><span class="headingEndMark"> — </span>Several retrospective studies have demonstrated that HLA matching is associated with a lower risk of acute rejection among kidney transplant recipients [<a href="#rid84">84,90,91</a>]. Although most of these studies were performed in patients receiving cyclosporine-based immunosuppression [<a href="#rid90">90,91</a>], one study showed that the number of HLA mismatches was an independent risk factor for acute rejection (odds ratio [OR] 1.65 per HLA mismatch) in transplant patients receiving immunosuppression consisting of interleukin (IL)-2 receptor antibody induction, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, and glucocorticoids [<a href="#rid84">84</a>]. Analyses of data from two large transplant registries found that the association between HLA mismatches and acute-rejection risk was independent of the transplant era and initial immunosuppressive regimen [<a href="#rid7">7,9</a>].</p><p class="headingAnchor" id="H1817680211"><span class="h2">Other transplant outcomes</span></p><p class="headingAnchor" id="H86356999"><span class="h3">Death with a functioning graft</span><span class="headingEndMark"> — </span>HLA mismatching has been associated with a higher risk of death with a functioning kidney allograft. In a study of 177,584 deceased-donor kidney transplants performed between 1990 and 2009, the incidence of death with a functioning graft was 4.8 percent during the first posttransplant year and 7.7 percent during years 2 through 5 (approximately 2 percent per year) [<a href="#rid92">92</a>]. The number of HLA-A, -B, and -DR mismatches correlated with a higher cumulative incidence of death with a functioning graft, from any cause, during the first three years posttransplant. This association was significant for death due to cardiovascular or infectious causes but not from malignancy.</p><p class="headingAnchor" id="H667064001"><span class="h3">Posttransplant lymphoproliferative disorders</span><span class="headingEndMark"> — </span>Several studies have shown that HLA mismatching is an independent risk factor for the development of posttransplant non-Hodgkin lymphoma among kidney transplant recipients [<a href="#rid93">93-96</a>]. As an example, in a study of 152,728 deceased-donor kidney transplant recipients from the Collaborative Transplant Study (CTS), an increased risk of posttransplant non-Hodgkin lymphoma was observed in patients with one (hazard ratio [HR] 1.21, 95% CI 1.00-1.45) and two (HR 1.56, 95% CI 1.21-1.99) HLA-DR mismatches [<a href="#rid93">93</a>]. Similar findings were reported in an analysis of 9209 pediatric kidney transplant recipients, in which two HLA-DR mismatches were associated with a twofold higher risk of developing posttransplant non-Hodgkin lymphoma [<a href="#rid94">94</a>]. (See  <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders", section on 'Others'</a>.)</p><p class="headingAnchor" id="H3331306767"><span class="h3">Posttransplant bone fractures</span><span class="headingEndMark"> — </span>HLA mismatches are associated with an increased risk of posttransplant bone fractures in kidney transplant recipients. In a retrospective study of 68,814 patients who were transplanted between 1988 and 1998, HLA mismatches were associated with a 9 percent increase in the risk of bone fractures within five years of transplant compared with patients with no mismatch [<a href="#rid97">97</a>]. Similarly, an analysis of 20,509 kidney transplant recipients from the CTS reported a higher risk of posttransplant hip fractures among patients with one (HR 1.85, 95% CI 1.18-2.89) and two (HR 2.24, 95% CI 1.25-4.02) HLA-DR mismatches.</p><p>The mechanism behind this association between HLA mismatching and bone fractures is uncertain. HLA mismatches are associated with a higher risk of acute rejection, which is generally treated with more intensive immunosuppression that could adversely affect bone quality. (See  <a class="medical medical_review" href="/z/d/html/100623.html" rel="external">"Kidney transplantation in adults: Bone disease after kidney transplantation", section on 'Pathogenesis and risk factors'</a>.)</p><p class="headingAnchor" id="H241222481"><span class="h1">HLA MATCHING AND ORGAN ALLOCATION</span></p><p class="headingAnchor" id="H4228699709"><span class="h2">Deceased-donor transplantation</span><span class="headingEndMark"> — </span>A limitation of strictly using human leukocyte antigen (HLA) typing for organ allocation is the difficulty in finding well-matched kidneys. The United States United Network for Organ Sharing (UNOS) program mandates that six-antigen-matched grafts be given priority. Despite the large registered waiting list and relative ease of shipping kidneys around the country, only 13 percent of recipients of deceased-donor kidneys are well matched, as defined by the six antigen matching criteria [<a href="#rid79">79</a>].</p><p>Priority shipping of organs is not limited to six-antigen-matched grafts, as zero antigen mismatching is also given priority. This occurred following two amendments to the original ruling by UNOS: the first to allow donors and recipients that were both homozygous for one antigen to be considered phenotypically matched and the second to allow for the shipment of zero-antigen-mismatched kidneys. With zero-antigen-mismatched kidneys, the donor does not express any antigen different from the recipient, although the recipient may have an antigen that is not expressed by the donor [<a href="#rid79">79</a>].</p><p>From January 2009 until December 3, 2014, only patients with calculated panel reactive antibodies (cPRAs) greater than 20 percent were allowed to be considered for the zero-antigen-mismatch program (UNOS). This policy was based upon the recognition that the expense of transportation and the negative effects of prolonged cold ischemia mitigated against improved short-term graft survival.</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fmedia%2Feavh5bf3%2Foptn_policies.pdf&amp;token=669kBvF2tWrkwig2IvBrpLus80Kv65lmC5j0EJDs9Efe%2FTTxxKhKejHjlxpkWyHSyIa4SQ1MWo1Wjpe8ADqrBT8iFKYXDAc4cjL%2BIW7n0Cc%3D&amp;TOPIC_ID=7355" target="_blank">kidney allocation system (KAS)</a> implemented on December 4, 2014 was designed to balance equity and utility of allocated organs and incorporated the kidney donor profile index (KDPI; measurement of organ quality) and the estimated posttransplant survival (EPTS; measurement of candidates expected longevity). In this allocation schema, zero-antigen-mismatched kidneys with KDPI scores &lt;20 percent would be primarily allocated to patients with EPTS scores &lt;20 percent (those expected to experience longer years of graft function) at the national, local, and regional level. Allocation points and priority are also given for HLA-DR matching. (See  <a class="medical medical_review" href="/z/d/html/7337.html" rel="external">"Kidney transplantation in adults: Organ sharing"</a>.)</p><p>Patients who receive an organ with more than 36 hours of cold ischemia time may not benefit from HLA matching. In an analysis of the UNOS database, recipients of zero-antigen-mismatched kidneys with less than 36 hours of cold ischemia time had superior five-year graft survival than recipients with one or more mismatches (75 and 67 percent, respectively, p&lt;0.001) [<a href="#rid98">98</a>]. However, no survival advantage was observed if zero-antigen-mismatched kidneys were exposed to more than 36 hours of cold ischemia time.</p><p>Thus, if there were no cold-ischemia-time effects, a strategy of national allocation and shipping of all kidneys (not just zero antigen mismatches) to minimize HLA mismatches would generate the largest graft survival improvement and cost savings [<a href="#rid99">99</a>]. However, there would be longer preservation times under a national allocation policy, and prolongation of cold ischemia time negatively affects outcome and costs. The early results of the newer KAS suggest that there is more shipping of organs, especially for highly sensitized patients [<a href="#rid100">100</a>]<em>.</em></p><p class="headingAnchor" id="H789243923"><span class="h2">Underrepresented groups</span><span class="headingEndMark"> — </span>The distribution of HLA antigens and frequency of deceased-donor donation differs among racial groups, thereby affecting organ allocation. Until the 2009 changes in the UNOS organ allocation policy, 17 percent of all standard criteria donor (SCD), deceased-donor kidneys were transplanted into zero-antigen-mismatched recipients [<a href="#rid80">80</a>], of whom approximately 90 percent were White patients and only 9 percent were Black patients [<a href="#rid101">101</a>]. Between 1987 and 1995, Black patients received only 6 percent of fully matched kidneys despite constituting approximately one-third of the national waiting list. Conversely, 30 percent of partially or fully mismatched kidneys go to recipients from underrepresented groups, approximating the frequency with which these patients appear on the waiting list.</p><p>To address this relative inequity, the national allocation policy of the United States was changed to no longer give priority points for fewer HLA-B mismatches. This was derived in part from findings of a study that addressed the effect of eliminating HLA-B matching. Based upon a Cox model analysis in which HLA-DR but not HLA-B matching was utilized, the number of transplants was calculated to decrease by 4 percent among White patients but increase by 6.3 percent in patients of other races [<a href="#rid102">102</a>]; this change was determined to result only in a 2 percent increase in graft loss. By comparison, removal of both HLA-B and HLA-DR would result in an 8 percent increase in graft loss. A study modeling the impact of this policy demonstrated that it would result in a detrimental effect on survival of White patients and overall increased costs [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H2235804556"><span class="h2">Pediatric patients</span><span class="headingEndMark"> — </span>Transplantation of pediatric patients presents additional challenges since these patients are more likely to require repeated transplantation. Thus, well-matched organs are a priority for pediatric patients and could potentially lead to longer wait times. This is in contradiction to the clinical management of pediatric patients where reducing time on dialysis is a more important objective since this impacts their neurologic development and growth. For this reason, all allocation systems (including Share 35 and the new KAS) have focused on quicker access to deceased kidney donors for pediatric transplant candidates [<a href="#rid104">104,105</a>]. These allocation changes have also allowed pediatric patients to receive the highest-quality donors (ie, those less than 35 years old and with a KDPI of 35 percent or less) [<a href="#rid106">106</a>]. Pediatric patients also receive priority points for HLA-DR matching. (See  <a class="medical medical_review" href="/z/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes", section on 'Human leukocyte antigen matches'</a>.)</p><p>Clinicians are conflicted between waiting for an HLA well-matched, deceased-donor organ or selecting a less well-matched living donor for their pediatric transplant candidates. In a study that analyzed the impact of HLA matching on outcomes among 3687 pediatric kidney transplant recipients, 10-year graft survival of kidneys from well-matched deceased donors with zero to one HLA mismatch was comparable to that of kidneys from less well-matched living donors with four to six HLA mismatches [<a href="#rid107">107</a>]. These findings suggest that living-donor pediatric kidney transplantation should ideally be performed from donors with fewer than four HLA-A+, -B+, -DR mismatches.</p><p class="headingAnchor" id="H7575313"><span class="h1">HLA MATCHING AND SIMULTANEOUS ORGAN TRANSPLANTATION</span><span class="headingEndMark"> — </span>When kidneys are transplanted along with another organ, human leukocyte antigen (HLA) matching may take a backseat to urgency of transplantation, as is the case for simultaneous heart-kidney (SHK) transplantation, or to evidence for a protective effect, as is the case for simultaneous liver-kidney (SLK) transplantation. The relevance of HLA mismatching in multiorgan transplantation has not been well studied, although an Organ Procurement Transplant Network/Scientific Registry of Transplant Recipient (OPTN/SRTR) report found a similar percentage of transplants with &gt;5 HLA-A, -B, -DR mismatches when multiorgan transplantation was compared with kidney transplantation alone (KTA; &gt;55 percent for SLK transplantation, &gt;50 percent for SHK transplantation, and &gt;45 percent for KTA) [<a href="#rid108">108,109</a>].</p><p class="headingAnchor" id="H3190157198"><span class="h1">IMPACT OF NON-HLA ANTIGENS</span><span class="headingEndMark"> — </span>A number of non-human leukocyte antigens (HLA) have been found to be important antibody targets and may impact transplant outcomes, as discussed below.</p><p class="headingAnchor" id="H2295172273"><span class="h2">MICA</span><span class="headingEndMark"> — </span>The major histocompatibility complex (MHC) class I-related chain A (MICA) is the product of an HLA-related, polymorphic gene [<a href="#rid110">110</a>]. MICA is expressed on monocytes, keratinocytes, fibroblasts, and endothelial cells. Although its exact function is unclear, MICA is recognized by a subpopulation of intestinal gamma delta T cells and may play a role in the activation of a subpopulation of natural killer cells [<a href="#rid111">111</a>].</p><p>Antibodies directed against MICA may adversely affect allograft function and survival [<a href="#rid112">112-116</a>]. This was shown in the following studies [<a href="#rid115">115,116</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 1920 recipients of kidney transplants, MICA antibodies were detected in 217 (11.4 percent) [<a href="#rid116">116</a>]. Compared with those without antibodies, the presence of MICA antibodies significantly lowered one-year allograft survival among all patients (88.3 versus 93 percent), recipients of first-kidney transplants (87.8 versus 93.5 percent), and recipients who received well-matched kidneys (zero or one HLA-A plus HLA-B plus HLA-DR mismatch; 83.2 versus 95.1 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As part of the 13<sup>th</sup> International Histocompatibility Workshop, 1329 patients with functioning transplants were prospectively tested for HLA antibodies in 2002 and followed for four years [<a href="#rid115">115</a>]. At four years, allograft survival was significantly higher among those with no identified antibodies (806 deceased-donor recipients) versus those with HLA (158 patients) or MICA antibodies (69 patients; 81 versus 58 and 72 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective trial of the 14<sup>th</sup> International Histocompatibility Workshop, one-year allograft survival of 1319 deceased-donor recipients and no HLA antibodies was 96 percent [<a href="#rid115">115</a>]. This was significantly higher than that observed for the 344 patients with HLA antibodies (94 percent) and the 33 patients with MICA antibodies (83 percent). By comparison, 12 recipients with donor-specific antibodies (DSAs) tested by single-antigen beads had a one-year graft survival of 64 percent, and 27 patients with non-donor-specific "strong" antibodies had a 66 percent survival.</p><p></p><p>These trials provide strong evidence that HLA and MICA antibodies are associated with graft failure after one and four years posttransplant. Some authors have therefore recommended universal testing of kidney transplant patients for antibodies against HLA as well as MICA posttransplantation and careful monitoring of serum creatinine levels if antibodies are detected.</p><p>However, testing for non-HLA antibodies is not widely performed. We test for such antibodies in select patients with evidence of antibody-mediated rejection (ABMR) without the presence of circulating donor-specific HLA antibodies.</p><p class="headingAnchor" id="H2172755185"><span class="h2">Angiotensin II type 1 receptor</span><span class="headingEndMark"> — </span>The angiotensin II type 1 receptor (AT1R) is a G protein-coupled receptor and one of the main components of the renin-angiotensin system (RAS). AT1R is expressed on endothelial and vascular smooth muscle cells [<a href="#rid117">117,118</a>], podocytes, and other kidney tissue [<a href="#rid119">119,120</a>]. Through the action of its natural ligand, angiotensin II, AT1R regulates blood flow, salt and water retention, aldosterone secretion, inflammation, and vascular remodeling [<a href="#rid121">121-123</a>]. Anti-AT1R antibodies have been detected in patients who have biopsy evidence of ABMR but do not have detectable DSAs [<a href="#rid124">124,125</a>].</p><p>The presence of anti-AT1R antibodies has been associated with poor kidney transplant outcomes including acute rejection and graft loss [<a href="#rid126">126-130</a>]. In vitro studies have shown that anti-AT1R antibodies isolated from the sera of transplant recipients can induce Erk signaling in endothelial and vascular smooth muscle cells in a similar fashion as the natural ligand, angiotensin II, resulting in the increased expression of inflammatory and coagulation proteins [<a href="#rid118">118,131-133</a>]. In addition, passive transfer of anti-AT1R antibody into healthy animals and anti-AT1R antibody stimulation of cultured cells result in phenotypic changes resembling vascular diseases, providing evidence that these antibodies are not only biomarkers but also contribute to disease pathogenesis [<a href="#rid134">134</a>].</p><p>By contrast, a few studies have found no correlation between the presence of anti-AT1R antibodies and kidney allograft outcomes [<a href="#rid135">135,136</a>].</p><p class="headingAnchor" id="H544644664"><span class="h2">H-Y antigen</span><span class="headingEndMark"> — </span>Due to reactivity against Y chromosome H-Y encoded gene products, transplants from a male donor to a female recipient, particularly hematopoietic cell transplants, are reportedly associated with an increased risk of rejection. However, the role of such gene products in kidney transplantation is unclear. This was indirectly evaluated in a retrospective cohort study of nearly 200,000 recipients of deceased-donor kidneys [<a href="#rid137">137</a>]. Compared with all other sex combinations, an increased risk of allograft failure was noted in female recipients of male-donor kidneys at one year (hazard ratio [HR] 1.08, 95% CI 1.03-1.14) and between 2 and 10 years (HR 1.06, 95% CI 1.01-1.10). These findings suggest that there may be an association between adverse effects and H-Y encoded products. Further studies are required to better understand this possible association.</p><p class="headingAnchor" id="H856314991"><span class="h2">Other non-HLA antigens</span><span class="headingEndMark"> — </span>Large-scale exome and genome sequencing technology has enabled the identification of other non-HLA genetic mismatches between kidney transplant recipients and their donors that could predict long-term graft survival [<a href="#rid138">138-140</a>]. In a genome-wide analysis of 477 pairs of deceased donors and first-kidney transplant recipients with stable graft function at three months posttransplant, genetic mismatches in non-synonymous single-nucleotide polymorphisms (nsSNPs) were quantified for genes encoding transmembrane or secreted proteins [<a href="#rid138">138</a>]. The number of nsSNP mismatches was predictive of graft loss after adjusting for HLA eplet mismatches (HR 1.68 per unit increase in interquartile range, 95% CI 1.17-2.41). Five-year death-censored graft survival was 98 percent in the quartile with the lowest number of nsSNP mismatches, 91 percent in the second quartile, 89 percent in the third quartile, and 82 percent in the highest quartile. DSAs directed against genetically predicted mismatched epitopes for some of the transmembrane proteins were identified among an independent cohort of 25 donor-recipient pairs with chronic ABMR. Although additional studies are needed to further characterize these non-HLA antigens, these findings support the important role of non-HLA alloimmunity in kidney transplantation and its impact on long-term transplant outcomes.</p><p>Genetic variants that cause disruptions (ie, deletions) in kidney genes may predispose a kidney transplant recipient to allosensitization and rejection, particularly if the recipient is homozygous for the deletion polymorphism and receives an organ from a donor who has at least one normal allele. This scenario, referred to as "genomic collision," was evaluated in a study that screened 705 kidney transplant recipients for 50 common gene-disrupting deletion polymorphisms [<a href="#rid141">141</a>]. Recipients who were homozygous for the specific single-nucleotide polymorphism rs893403 on chromosome 2q12.3 at the <em>LIMS1 </em>locus had a higher risk of acute rejection compared with recipients who did not have this genotype (HR 1.84, 95% CI 1.35-2.50). This finding was replicated in 2004 donor-recipient pairs from three independent transplant cohorts (HR 1.55, 95% 1.25-1.93). In addition, homozygosity for rs893403 was associated with the presence of serum antibodies against the LIMS1 protein. The results of this study identify <em>LIMS1</em> as a potential minor histocompatibility antigen and support genomic collision at the <em>LIMS1 </em>locus as a potential mechanism contributing to the risk of rejection in kidney transplant recipients.</p><p class="headingAnchor" id="H784385494"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H1452512943"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Human leukocyte antigen (HLA) matching between potential donors and transplant candidates is determined by comparing their HLA antigens. In the United States, Canada, and Europe, HLA typing for waitlisted kidney transplant candidates is performed by intermediate- or high-resolution molecular typing, and serologic equivalents for HLA-A, -B, -C, -Bw4, -Bw6, -DR, -DR51/52/53, and -DQB antigens are reported for organ sharing. (See <a class="local">'Introduction'</a> above and <a class="local">'Determination of HLA matching'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determination of HLA matching </strong>– The degree of mismatch between recipient and donor is primarily determined for HLA-A, -B, and -DR antigens. Thus, a <strong>zero antigen mismatch</strong> between a recipient and donor is defined as the absence of an HLA-A, -B, or -DR antigen in the donor's phenotype that is different from the recipient's HLA-A, -B, and -DR antigens. Conversely, a <strong>six antigen mismatch</strong> indicates that two A, two B, and two DR antigens in the donor's phenotype are different from those of the recipient. (See <a class="local">'Determination of HLA matching'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HLA mismatching and sensitization </strong>– The high polymorphism in the HLA system results in multiple variations of antigens. Consequently, transplant candidates often must receive an organ from a donor with one of several HLA-mismatched antigens. Exposure to an HLA antigen that is non-self can lead to development of antibodies against the mismatched HLA antigen(s). This is known as sensitization. (See <a class="local">'HLA mismatching and sensitization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HLA factors associated with transplant outcomes </strong>– Data from large registry studies have shown that a higher degree of HLA mismatching is associated with worse transplant outcomes. In addition, several studies have demonstrated that mismatches at individual HLA loci do not have equal weight with regards to transplant outcomes. In particular, there is a strong association between HLA matching at the HLA-A, -B, and -DR loci and patient and graft outcomes. (See <a class="local">'HLA factors associated with transplant outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeated mismatched HLA antigens </strong>– Reexposure to repeated mismatched HLA antigens may trigger reactivation of memory B cells and a rebound in donor-specific antibodies (DSA) immediately posttransplant, leading to earlier graft injury and loss. While the presence of repeated mismatched antigens associated with DSA is generally avoided in kidney transplantation, repeat mismatches alone in the absence of circulating DSA may <strong>not </strong>need to be categorically avoided, as this practice may further limit access to transplantation. (See <a class="local">'Repeated mismatched HLA antigens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies to optimize HLA matching </strong>– The likelihood of finding a fully HLA-matched, unrelated donor for every kidney transplant candidate is low. Alternative strategies have focused on matching based upon structural and conformational similarity among several of the HLA antigens. (See <a class="local">'Strategies to optimize HLA matching'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HLA matching and transplant outcomes </strong>– HLA matching has been associated with improved long-term graft survival and a lower risk of acute rejection among kidney transplant recipients. Although the survival of HLA-mismatched kidneys is reduced compared with HLA-matched kidneys, the survival of highly sensitized recipients of HLA-mismatched kidneys is higher when compared with highly sensitized transplant candidates who remain on the waiting list and are undergoing dialysis. HLA mismatching has been associated with an increased risk of death with a functioning graft, posttransplant lymphoproliferative disorders, and posttransplant bone fractures. (See <a class="local">'HLA matching and transplant outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HLA matching and organ allocation </strong>– A limitation of strictly using HLA typing for organ allocation is the difficulty in finding well-matched kidneys. The United States United Network for Organ Sharing (UNOS) program mandates that six-antigen-matched grafts be given priority. Despite the large registered waiting list and relative ease of shipping kidneys around the country, only 13 percent of recipients of deceased-donor kidneys are well matched. (See <a class="local">'HLA matching and organ allocation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of non-HLA antigens </strong>– A number of non-HLA antigens have been found to be important antibody targets and may impact transplant outcomes, including the major histocompatibility complex (MHC) class I-related chain A (MICA), angiotensin II type 1 receptor (AT1R), and the H-Y antigen. (See <a class="local">'Impact of non-HLA antigens'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cheigh JS, Chami J, Stenzel KH, et al. Renal transplantation between HLA identical siblings. Comparison with transplants from HLA semi-identical related donors. N Engl J Med 1977; 296:1030.</a></li><li><a class="nounderline abstract_t">Tambur AR, Kosmoliaptsis V, Claas FHJ, et al. Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen-matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney Int 2021; 100:1012.</a></li><li><a class="nounderline abstract_t">Audry B, Savoye E, Pastural M, et al. The new French kidney allocation system for donations after brain death: Rationale, implementation, and evaluation. Am J Transplant 2022; 22:2855.</a></li><li><a class="nounderline abstract_t">Yacoub R, Nadkarni GN, Cravedi P, et al. Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival. Kidney Int 2018; 93:482.</a></li><li><a class="nounderline abstract_t">Hafeez MS, Awais SB, Razvi M, et al. HLA mismatch is important for 20-year graft survival in kidney transplant patients. Transpl Immunol 2023; 80:101861.</a></li><li><a class="nounderline abstract_t">Williams RC, Opelz G, McGarvey CJ, et al. The Risk of Transplant Failure With HLA Mismatch in First Adult Kidney Allografts From Deceased Donors. Transplantation 2016; 100:1094.</a></li><li><a class="nounderline abstract_t">Lim WH, Chadban SJ, Clayton P, et al. Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients. Clin Transplant 2012; 26:E428.</a></li><li><a class="nounderline abstract_t">Shi X, Lv J, Han W, et al. What is the impact of human leukocyte antigen mismatching on graft survival and mortality in renal transplantation? A meta-analysis of 23 cohort studies involving 486,608 recipients. BMC Nephrol 2018; 19:116.</a></li><li><a class="nounderline abstract_t">Opelz G, Döhler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007; 84:137.</a></li><li><a class="nounderline abstract_t">Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11:2132.</a></li><li><a class="nounderline abstract_t">Opelz G. Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplantation 1985; 40:240.</a></li><li class="breakAll">Opelz, G. Collaborative Transplant Study Newsletter 1988; number 3. Available at: https://www.ctstransplant.org/public/newsletters/1988/1988-3.html?ts=5932027897731538 (Accessed on September 27, 2023).</li><li><a class="nounderline abstract_t">Gilks WR, Bradley BA, Gore SM, Klouda PT. Substantial benefits of tissue matching in renal transplantation. Transplantation 1987; 43:669.</a></li><li><a class="nounderline abstract_t">Doxiadis II, de Fijter JW, Mallat MJ, et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation 2007; 83:1207.</a></li><li><a class="nounderline abstract_t">Coupel S, Giral-Classe M, Karam G, et al. Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months. Kidney Int 2003; 64:674.</a></li><li><a class="nounderline abstract_t">Meier-Kriesche HU, Scornik JC, Susskind B, et al. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 2009; 88:23.</a></li><li><a class="nounderline abstract_t">Gralla J, Tong S, Wiseman AC. The impact of human leukocyte antigen mismatching on sensitization rates and subsequent retransplantation after first graft failure in pediatric renal transplant recipients. Transplantation 2013; 95:1218.</a></li><li><a class="nounderline abstract_t">Malfait T, Emonds MP, Daniëls L, et al. HLA Class II Antibodies at the Time of Kidney Transplantation and Cardiovascular Outcome: A Retrospective Cohort Study. Transplantation 2020; 104:823.</a></li><li><a class="nounderline abstract_t">Lim WH, Chapman JR, Coates PT, et al. HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients. Clin J Am Soc Nephrol 2016; 11:875.</a></li><li><a class="nounderline abstract_t">Leeaphorn N, Pena JRA, Thamcharoen N, et al. HLA-DQ Mismatching and Kidney Transplant Outcomes. Clin J Am Soc Nephrol 2018; 13:763.</a></li><li><a class="nounderline abstract_t">Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013; 95:1113.</a></li><li class="breakAll">The Organ Procurement Transplant Network. OPTN/UNOS Histocompatibility Committee AMENDED Report to the Board of Directors. November 8-9, 2010, St. Louis, MO. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf (Accessed on August 31, 2014).</li><li><a class="nounderline abstract_t">Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157.</a></li><li><a class="nounderline abstract_t">Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95:410.</a></li><li><a class="nounderline abstract_t">Tran TH, Döhler B, Heinold A, et al. Deleterious impact of mismatching for human leukocyte antigen-C in presensitized recipients of kidney transplants. Transplantation 2011; 92:419.</a></li><li><a class="nounderline abstract_t">Ling M, Marfo K, Masiakos P, et al. Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients. Hum Immunol 2012; 73:879.</a></li><li><a class="nounderline abstract_t">Bryan CF, Luger AM, Smith JL, et al. Sharing kidneys across donor-service area boundaries with sensitized candidates can be influenced by HLA C. Clin Transplant 2010; 24:56.</a></li><li><a class="nounderline abstract_t">Gilbert M, Paul S, Perrat G, et al. Impact of pretransplant human leukocyte antigen-C and -DP antibodies on kidney graft outcome. Transplant Proc 2011; 43:3412.</a></li><li><a class="nounderline abstract_t">Chapman JR, Taylor C, Ting A, Morris PJ. Hyperacute rejection of a renal allograft in the presence of anti-HLA-Cw5 antibody. Transplantation 1986; 42:91.</a></li><li><a class="nounderline abstract_t">Bachelet T, Couzi L, Guidicelli G, et al. Anti-Cw donor-specific alloantibodies can lead to positive flow cytometry crossmatch and irreversible acute antibody-mediated rejection. Am J Transplant 2011; 11:1543.</a></li><li><a class="nounderline abstract_t">Aubert O, Bories MC, Suberbielle C, et al. Risk of antibody-mediated rejection in kidney transplant recipients with anti-HLA-C donor-specific antibodies. Am J Transplant 2014; 14:1439.</a></li><li><a class="nounderline abstract_t">Pfeiffer K, Vögeler U, Albrecht KH, et al. HLA-DP antibodies in patients awaiting renal transplantation. Transpl Int 1995; 8:180.</a></li><li><a class="nounderline abstract_t">Qiu J, Cai J, Terasaki PI, et al. Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads. Transplantation 2005; 80:1511.</a></li><li><a class="nounderline abstract_t">Youngs D. HLA-DP alloantibodies. ASHI Quarterly 2004; 28:60.</a></li><li><a class="nounderline abstract_t">Laux G, Mansmann U, Deufel A, et al. A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation 2003; 75:1527.</a></li><li><a class="nounderline abstract_t">Nelson KA, Youngs D, Marks MH. Acute humoral rejection is associated with antibodies to HLA-DP. Am J Transplant 2005; 5:245.</a></li><li><a class="nounderline abstract_t">Samaniego M, Mezrich J, Torrealba J, et al. C4d-positive acute antibody-mediated rejection due to anti-HLA-DP antibody: a tale of one patient and a review of the University of Wisconsin experience. Clin Transpl 2006; :503.</a></li><li><a class="nounderline abstract_t">Goral S, Prak EL, Kearns J, et al. Preformed donor-directed anti-HLA-DP antibodies may be an impediment to successful kidney transplantation. Nephrol Dial Transplant 2008; 23:390.</a></li><li><a class="nounderline abstract_t">Singh P, Colombe BW, Francos GC, et al. Acute humoral rejection in a zero mismatch deceased donor renal transplant due to an antibody to an HLA-DP alpha. Transplantation 2010; 90:220.</a></li><li><a class="nounderline abstract_t">Jolly EC, Key T, Rasheed H, et al. Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation. Am J Transplant 2012; 12:2845.</a></li><li><a class="nounderline abstract_t">Zachary AA, Lucas DP, Montgomery RA, Leffell MS. Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 2013; 95:701.</a></li><li><a class="nounderline abstract_t">Lúcia M, Luque S, Crespo E, et al. Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation. Kidney Int 2015; 88:874.</a></li><li><a class="nounderline abstract_t">Snanoudj R, Claas FH, Heidt S, et al. Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. Kidney Int 2015; 87:1230.</a></li><li><a class="nounderline abstract_t">Ting A, Morris PJ. Renal transplantation and B-cell cross-matches with autoantibodies and alloantibodies. Lancet 1977; 2:1095.</a></li><li><a class="nounderline abstract_t">Opelz G. Repeated HLA mismatches increase the failure rate of second kidney transplants. Collaborative Transplant Study. Transplant Proc 1995; 27:658.</a></li><li><a class="nounderline abstract_t">Cecka JM, Terasaki PI. Repeating HLA antigen mismatches in renal retransplants--a second class mistake? Transplantation 1994; 57:515.</a></li><li><a class="nounderline abstract_t">House AA, Chang PC, Luke PP, et al. Re-exposure to mismatched HLA class I is a significant risk factor for graft loss: multivariable analysis of 259 kidney retransplants. Transplantation 2007; 84:722.</a></li><li><a class="nounderline abstract_t">Opelz G, Terasaki PI. Absence of immunization effect in human-kidney retransplantation. N Engl J Med 1978; 299:369.</a></li><li><a class="nounderline abstract_t">Farney AC, Matas AJ, Noreen HJ, et al. Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival? Clin Transplant 1996; 10:147.</a></li><li><a class="nounderline abstract_t">Tinckam KJ, Rose C, Hariharan S, Gill J. Re-Examining Risk of Repeated HLA Mismatch in Kidney Transplantation. J Am Soc Nephrol 2016; 27:2833.</a></li><li><a class="nounderline abstract_t">Caskey FJ, Johnson RJ, Fuggle SV, et al. Renal after cardiothoracic transplant: the effect of repeat mismatches on outcome. Transplantation 2009; 87:1727.</a></li><li><a class="nounderline abstract_t">Mjörnstedt L, Konar J, Nyberg G, et al. Renal retransplantation in patients with HLA-antibodies. Transpl Int 1992; 5 Suppl 1:S32.</a></li><li><a class="nounderline abstract_t">Gjertson DW. A multi-factor analysis of kidney regraft outcomes. Clin Transpl 2002; :335.</a></li><li><a class="nounderline abstract_t">Burlingham WJ, Grailer AP, Heisey DM, et al. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. N Engl J Med 1998; 339:1657.</a></li><li><a class="nounderline abstract_t">Sanfilippo F. Transplantation tolerance--the search continues. N Engl J Med 1998; 339:1700.</a></li><li><a class="nounderline abstract_t">Duquesnoy RJ. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 2002; 63:339.</a></li><li><a class="nounderline abstract_t">El-Awar N, Cook D, Terasaki PI. HLA class I epitopes: A and B loci. Clin Transpl 2006; :79.</a></li><li><a class="nounderline abstract_t">Kosmoliaptsis V, Bradley JA, Sharples LD, et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008; 85:1817.</a></li><li><a class="nounderline abstract_t">Claas F, Castelli-Visser R, Schreuder I, van Rood J. Allo-antibodies to an antigenic determinant shared by HLA-A2 and B17. Tissue Antigens 1982; 19:388.</a></li><li><a class="nounderline abstract_t">Schwartz BD, Luehrman LK, Rodey GE. Public antigenic determinant on a family of HLA-B molecules. J Clin Invest 1979; 64:938.</a></li><li><a class="nounderline abstract_t">Fuller AA, Rodey GE, Parham P, Fuller TC. Epitope map of the HLA-B7 CREG using affinity-purified human alloantibody probes. Hum Immunol 1990; 28:306.</a></li><li><a class="nounderline abstract_t">Starzl TE, Eliasziw M, Gjertson D, et al. HLA and cross-reactive antigen group matching for cadaver kidney allocation. Transplantation 1997; 64:983.</a></li><li><a class="nounderline abstract_t">Sijpkens YW, Doxiadis II, De Fijter JW, et al. Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 1999; 56:1920.</a></li><li><a class="nounderline abstract_t">Laux G, Opelz G. Immunological relevance of CREG matching in cadaver kidney transplantation. Transplantation 2004; 78:442.</a></li><li><a class="nounderline abstract_t">Charnaya O, Jones J, Philogene MC, et al. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients. Pediatr Nephrol 2021; 36:3971.</a></li><li><a class="nounderline abstract_t">Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013; 13:3114.</a></li><li><a class="nounderline abstract_t">Dankers MK, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004; 77:1236.</a></li><li><a class="nounderline abstract_t">Kosmoliaptsis V, Mallon DH, Chen Y, et al. Alloantibody Responses After Renal Transplant Failure Can Be Better Predicted by Donor-Recipient HLA Amino Acid Sequence and Physicochemical Disparities Than Conventional HLA Matching. Am J Transplant 2016; 16:2139.</a></li><li><a class="nounderline abstract_t">Senev A, Coemans M, Lerut E, et al. Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study. J Am Soc Nephrol 2020; 31:2193.</a></li><li><a class="nounderline abstract_t">Wiebe C, Nevins TE, Robiner WN, et al. The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival. Am J Transplant 2015; 15:2197.</a></li><li><a class="nounderline abstract_t">Dankers MK, Heemskerk MB, Duquesnoy RJ, et al. HLAMatchmaker algorithm is not a suitable tool to predict the alloreactive cytotoxic T-lymphocyte response in vitro. Transplantation 2004; 78:165.</a></li><li><a class="nounderline abstract_t">Lachmann N, Niemann M, Reinke P, et al. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation. Am J Transplant 2017; 17:3076.</a></li><li><a class="nounderline abstract_t">Geneugelijk K, Niemann M, Drylewicz J, et al. PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. Front Immunol 2018; 9:321.</a></li><li><a class="nounderline abstract_t">Bryan CF, Chadha V, Warady BA. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm. Pediatr Transplant 2016; 20:926.</a></li><li><a class="nounderline abstract_t">Kausman JY, Walker AM, Cantwell LS, et al. Application of an epitope-based allocation system in pediatric kidney transplantation. Pediatr Transplant 2016; 20:931.</a></li><li><a class="nounderline abstract_t">Tambur AR. HLA-Epitope Matching or Eplet Risk Stratification: The Devil Is in the Details. Front Immunol 2018; 9:2010.</a></li><li><a class="nounderline abstract_t">Lucas DP, Leffell MS, Zachary AA. Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response. Transplantation 2015; 99:77.</a></li><li><a class="nounderline abstract_t">McCaughan JA, Battle RK, Singh SKS, et al. Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation. Am J Transplant 2018; 18:2924.</a></li><li><a class="nounderline abstract_t">Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343:1078.</a></li><li class="breakAll">The Scientific Registry of Transplant Recipients http://www.ustransplant.org (Accessed on February 02, 2010).</li><li class="breakAll">Cecka JM, Terasaki PI. The UNOS Renal Transplant Registry. In: Clinical Transplants 1993, Terasaki PI, Cecka JM (Eds), UCLA Tissue Typing Laboratory, Los Angeles 1994. p.1.</li><li><a class="nounderline abstract_t">Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342:605.</a></li><li><a class="nounderline abstract_t">Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Interaction of mycophenolate mofetil and HLA matching on renal allograft survival. Transplantation 2001; 71:398.</a></li><li><a class="nounderline abstract_t">Wissing KM, Fomegné G, Broeders N, et al. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 2008; 85:411.</a></li><li><a class="nounderline abstract_t">Su X, Zenios SA, Chakkera H, et al. Diminishing significance of HLA matching in kidney transplantation. Am J Transplant 2004; 4:1501.</a></li><li class="breakAll">http://www.ustransplant.org (Accessed on February 02, 2010).</li><li><a class="nounderline abstract_t">Andresdottir MB, Hoitsma AJ, Assmann KJ, et al. The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts. Transplantation 1999; 68:623.</a></li><li><a class="nounderline abstract_t">Orandi BJ, Luo X, Massie AB, et al. Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. N Engl J Med 2016; 374:940.</a></li><li><a class="nounderline abstract_t">Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318.</a></li><li><a class="nounderline abstract_t">Beckingham IJ, Dennis MJ, Bishop MC, et al. Effect of human leucocyte antigen matching on the incidence of acute rejection in renal transplantation. Br J Surg 1994; 81:574.</a></li><li><a class="nounderline abstract_t">McKenna RM, Lee KR, Gough JC, et al. Matching for private or public HLA epitopes reduces acute rejection episodes and improves two-year renal allograft function. Transplantation 1998; 66:38.</a></li><li><a class="nounderline abstract_t">Opelz G, Döhler B. Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report. Am J Transplant 2012; 12:3031.</a></li><li><a class="nounderline abstract_t">Opelz G, Döhler B. Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation. Transplantation 2010; 89:567.</a></li><li><a class="nounderline abstract_t">Opelz G, Döhler B. Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report. Transplantation 2010; 90:292.</a></li><li><a class="nounderline abstract_t">Hussain SK, Makgoeng SB, Everly MJ, et al. HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation. Transplantation 2016; 100:2453.</a></li><li><a class="nounderline abstract_t">Caillard S, Lamy FX, Quelen C, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012; 12:682.</a></li><li><a class="nounderline abstract_t">Nikkel LE, Hollenbeak CS, Fox EJ, et al. Risk of fractures after renal transplantation in the United States. Transplantation 2009; 87:1846.</a></li><li><a class="nounderline abstract_t">Lee CM, Carter JT, Alfrey EJ, et al. Prolonged cold ischemia time obviates the benefits of 0 HLA mismatches in renal transplantation. Arch Surg 2000; 135:1016.</a></li><li><a class="nounderline abstract_t">Schnitzler MA, Hollenbeak CS, Cohen DS, et al. The economic implications of HLA matching in cadaveric renal transplantation. N Engl J Med 1999; 341:1440.</a></li><li class="breakAll">OPTN. Kidney Allocation System (KAS) "Out-of-the-gate" Monitoring Report. January 15, 2015. http://optn.transplant.hrsa.gov/media/1142/kas_monitoring_report.pdf (Accessed on February 18, 2015).</li><li><a class="nounderline abstract_t">Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med 2000; 343:1545.</a></li><li><a class="nounderline abstract_t">Roberts JP, Wolfe RA, Bragg-Gresham JL, et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 2004; 350:545.</a></li><li><a class="nounderline abstract_t">Mutinga N, Brennan DC, Schnitzler MA. Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation. Am J Transplant 2005; 5:1090.</a></li><li><a class="nounderline abstract_t">Amaral S, Patzer RE, Kutner N, McClellan W. Racial disparities in access to pediatric kidney transplantation since share 35. J Am Soc Nephrol 2012; 23:1069.</a></li><li><a class="nounderline abstract_t">Amaral S, Patzer R. Disparities, race/ethnicity and access to pediatric kidney transplantation. Curr Opin Nephrol Hypertens 2013; 22:336.</a></li><li><a class="nounderline abstract_t">Nazarian SM, Peng AW, Duggirala B, et al. The kidney allocation system does not appropriately stratify risk of pediatric donor kidneys: Implications for pediatric recipients. Am J Transplant 2018; 18:574.</a></li><li><a class="nounderline abstract_t">Opelz G, Döhler B, Middleton D, et al. HLA Matching in Pediatric Kidney Transplantation: HLA Poorly Matched Living Donor Transplants Versus HLA Well-Matched Deceased Donor Transplants. Transplantation 2017; 101:2789.</a></li><li><a class="nounderline abstract_t">Kwong AJ, Kim WR, Lake JR, et al. OPTN/SRTR 2019 Annual Data Report: Liver. Am J Transplant 2021; 21 Suppl 2:208.</a></li><li><a class="nounderline abstract_t">Colvin M, Smith JM, Hadley N, et al. OPTN/SRTR 2018 Annual Data Report: Heart. Am J Transplant 2020; 20 Suppl s1:340.</a></li><li><a class="nounderline abstract_t">Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 1994; 91:6259.</a></li><li><a class="nounderline abstract_t">Zwirner NW, Marcos CY, Mirbaha F, et al. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol 2000; 61:917.</a></li><li><a class="nounderline abstract_t">Zou Y, Heinemann FM, Grosse-Wilde H, et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006; 67:230.</a></li><li><a class="nounderline abstract_t">Sumitran-Karuppan S, Tyden G, Reinholt F, et al. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997; 5:321.</a></li><li><a class="nounderline abstract_t">Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5:2265.</a></li><li><a class="nounderline abstract_t">Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408.</a></li><li><a class="nounderline abstract_t">Zou Y, Stastny P, Süsal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357:1293.</a></li><li><a class="nounderline abstract_t">Kill A, Tabeling C, Undeutsch R, et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 2014; 16:R29.</a></li><li><a class="nounderline abstract_t">Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558.</a></li><li><a class="nounderline abstract_t">Jang HS, Kim JI, Kim J, et al. Angiotensin II removes kidney resistance conferred by ischemic preconditioning. Biomed Res Int 2014; 2014:602149.</a></li><li><a class="nounderline abstract_t">Harrison-Bernard LM, Navar LG, Ho MM, et al. Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol 1997; 273:F170.</a></li><li><a class="nounderline abstract_t">Inagami T. The renin-angiotensin system. Essays Biochem 1994; 28:147.</a></li><li><a class="nounderline abstract_t">Inagami T, Kambayashi Y, Ichiki T, et al. Angiotensin receptors: molecular biology and signalling. Clin Exp Pharmacol Physiol 1999; 26:544.</a></li><li><a class="nounderline abstract_t">Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977; 57:313.</a></li><li><a class="nounderline abstract_t">Lim MA, Palmer M, Trofe-Clark J, et al. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies. Hum Immunol 2017; 78:350.</a></li><li><a class="nounderline abstract_t">Philogene MC, Bagnasco S, Kraus ES, et al. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies. Transplantation 2017; 101:608.</a></li><li><a class="nounderline abstract_t">Jobert A, Rao N, Deayton S, et al. Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney transplantation. Nephrology (Carlton) 2015; 20 Suppl 1:10.</a></li><li><a class="nounderline abstract_t">Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep 2014; 16:431.</a></li><li><a class="nounderline abstract_t">Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90:1473.</a></li><li><a class="nounderline abstract_t">Lee J, Huh KH, Park Y, et al. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. Nephrol Dial Transplant 2017; 32:1244.</a></li><li><a class="nounderline abstract_t">Malheiro J, Tafulo S, Dias L, et al. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies. Nephrology (Carlton) 2019; 24:347.</a></li><li><a class="nounderline abstract_t">Dragun D. Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol Dial Transplant 2007; 22:1819.</a></li><li><a class="nounderline abstract_t">Dechend R, Homuth V, Wallukat G, et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000; 101:2382.</a></li><li><a class="nounderline abstract_t">Pearl MH, Zhang Q, Palma Diaz MF, et al. Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation. Kidney Int 2018; 93:260.</a></li><li><a class="nounderline abstract_t">Lukitsch I, Kehr J, Chaykovska L, et al. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 2012; 94:8.</a></li><li><a class="nounderline abstract_t">Pinelli DF, Friedewald JJ, Haarberg KMK, et al. Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome. Hum Immunol 2017; 78:421.</a></li><li><a class="nounderline abstract_t">Deltombe C, Gillaizeau F, Anglicheau D, et al. Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study. Transpl Int 2017; 30:1150.</a></li><li><a class="nounderline abstract_t">Gratwohl A, Döhler B, Stern M, Opelz G. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet 2008; 372:49.</a></li><li><a class="nounderline abstract_t">Reindl-Schwaighofer R, Heinzel A, Kainz A, et al. Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort. Lancet 2019; 393:910.</a></li><li><a class="nounderline abstract_t">Mesnard L, Muthukumar T, Burbach M, et al. Exome Sequencing and Prediction of Long-Term Kidney Allograft Function. PLoS Comput Biol 2016; 12:e1005088.</a></li><li><a class="nounderline abstract_t">Pineda S, Sigdel TK, Chen J, et al. Novel Non-Histocompatibility Antigen Mismatched Variants Improve the Ability to Predict Antibody-Mediated Rejection Risk in Kidney Transplant. Front Immunol 2017; 8:1687.</a></li><li><a class="nounderline abstract_t">Steers NJ, Li Y, Drace Z, et al. Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection. N Engl J Med 2019; 380:1918.</a></li></ol></div><div id="topicVersionRevision">Topic 7355 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/139567" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Renal transplantation between HLA identical siblings. Comparison with transplants from HLA semi-identical related donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34246656" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen-matching priorities to improve transplant outcomes? An expert review and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36000787" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The new French kidney allocation system for donations after brain death: Rationale, implementation, and evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28965746" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37302557" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : HLA mismatch is important for 20-year graft survival in kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26901078" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Risk of Transplant Failure With HLA Mismatch in First Adult Kidney Allografts From Deceased Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22672477" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29776389" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : What is the impact of human leukocyte antigen mismatching on graft survival and mortality in renal transplantation? A meta-analysis of 23 cohort studies involving 486,608 recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17667803" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812918" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Revisiting traditional risk factors for rejection and graft loss after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3898488" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3898488" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3554659" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Substantial benefits of tissue matching in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17496537" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12846765" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584676" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23478360" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The impact of human leukocyte antigen mismatching on sensitization rates and subsequent retransplantation after first graft failure in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31369517" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : HLA Class II Antibodies at the Time of Kidney Transplantation and Cardiovascular Outcome: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27034399" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29685925" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : HLA-DQ Mismatching and Kidney Transplant Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514959" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514959" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22429309" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380861" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21743387" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Deleterious impact of mismatching for human leukocyte antigen-C in presensitized recipients of kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22841893" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20015269" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sharing kidneys across donor-service area boundaries with sensitized candidates can be influenced by HLA C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22099809" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of pretransplant human leukocyte antigen-C and -DP antibodies on kidney graft outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3523890" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hyperacute rejection of a renal allograft in the presence of anti-HLA-Cw5 antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668642" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Anti-Cw donor-specific alloantibodies can lead to positive flow cytometry crossmatch and irreversible acute antibody-mediated rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24804568" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk of antibody-mediated rejection in kidney transplant recipients with anti-HLA-C donor-specific antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7626176" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : HLA-DP antibodies in patients awaiting renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16340798" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : HLA-DP alloantibodies</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792509" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute humoral rejection is associated with antibodies to HLA-DP</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18365412" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : C4d-positive acute antibody-mediated rejection due to anti-HLA-DP antibody: a tale of one patient and a review of the University of Wisconsin experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17956891" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Preformed donor-directed anti-HLA-DP antibodies may be an impediment to successful kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644454" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acute humoral rejection in a zero mismatch deceased donor renal transplant due to an antibody to an HLA-DP alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22759079" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23503502" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26176829" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25565312" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/73008" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Renal transplantation and B-cell cross-matches with autoantibodies and alloantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7879134" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Repeated HLA mismatches increase the failure rate of second kidney transplants. Collaborative Transplant Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8116035" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Repeating HLA antigen mismatches in renal retransplants--a second class mistake?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17893605" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Re-exposure to mismatched HLA class I is a significant risk factor for graft loss: multivariable analysis of 259 kidney retransplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/353556" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Absence of immunization effect in human-kidney retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664509" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888475" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Re-Examining Risk of Repeated HLA Mismatch in Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19502967" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Renal after cardiothoracic transplant: the effect of repeat mismatches on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14621726" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Renal retransplantation in patients with HLA-antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12971460" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A multi-factor analysis of kidney regraft outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9834302" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9834310" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Transplantation tolerance--the search continues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11975978" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18365370" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : HLA class I epitopes: A and B loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18580476" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6180520" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Allo-antibodies to an antigenic determinant shared by HLA-A2 and B17.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/90060" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Public antigenic determinant on a family of HLA-B molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1695624" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Epitope map of the HLA-B7 CREG using affinity-purified human alloantibody probes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9381546" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : HLA and cross-reactive antigen group matching for cadaver kidney allocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571803" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sharing cross-reactive groups of MHC class I improves long-term graft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316374" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Immunological relevance of CREG matching in cadaver kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34100108" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24164958" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15114091" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26755448" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Alloantibody Responses After Renal Transplant Failure Can Be Better Predicted by Donor-Recipient HLA Amino Acid Sequence and Physicochemical Disparities Than Conventional HLA Matching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32764139" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26095765" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15257058" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : HLAMatchmaker algorithm is not a suitable tool to predict the alloreactive cytotoxic T-lymphocyte response in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28613392" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29556227" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : PIRCHE-II Is Related to Graft Failure after Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27448994" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27662811" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Application of an epitope-based allocation system in pediatric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30233594" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : HLA-Epitope Matching or Eplet Risk Stratification: The Devil Is in the Details.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25187165" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29847022" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11027742" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11027742" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11027742" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699159" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Improved graft survival after renal transplantation in the United States, 1988 to 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11233900" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Interaction of mycophenolate mofetil and HLA matching on renal allograft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322434" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307838" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Diminishing significance of HLA matching in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307838" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Diminishing significance of HLA matching in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10507479" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26962729" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793744" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Desensitization in HLA-incompatible kidney recipients and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205440" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effect of human leucocyte antigen matching on the incidence of acute rejection in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9679819" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Matching for private or public HLA epitopes reduces acute rejection episodes and improves two-year renal allograft function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22900931" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20110857" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20548266" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26636741" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22226336" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19543063" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Risk of fractures after renal transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10982503" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Prolonged cold ischemia time obviates the benefits of 0 HLA mismatches in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10547408" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The economic implications of HLA matching in cadaveric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10547408" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The economic implications of HLA matching in cadaveric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11087885" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Renal transplantation in black Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14762181" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15816891" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22539831" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Racial disparities in access to pediatric kidney transplantation since share 35.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23508056" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Disparities, race/ethnicity and access to pediatric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28805300" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The kidney allocation system does not appropriately stratify risk of pediatric donor kidneys: Implications for pediatric recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28471872" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : HLA Matching in Pediatric Kidney Transplantation: HLA Poorly Matched Living Donor Transplants Versus HLA Well-Matched Deceased Donor Transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33595192" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : OPTN/SRTR 2019 Annual Data Report: Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31898418" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : OPTN/SRTR 2018 Annual Data Report: Heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8022771" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A second lineage of mammalian major histocompatibility complex class I genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053635" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16698447" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9504155" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16095508" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229080" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898098" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Antibodies against MICA antigens and kidney-transplant rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24472528" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15703421" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25243156" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Angiotensin II removes kidney resistance conferred by ischemic preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9249605" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7925317" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The renin-angiotensin system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10405785" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Angiotensin receptors: molecular biology and signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/191856" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Renin-angiotensin system: biochemistry and mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28284829" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27222934" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25807851" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24760441" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Angiotensin II and vascular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030904" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26546592" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29451342" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17517802" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10821814" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28927645" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691955" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28372986" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28686316" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18603158" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30773281" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27684477" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Exome Sequencing and Prediction of Long-Term Kidney Allograft Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29259604" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Novel Non-Histocompatibility Antigen Mismatched Variants Improve the Ability to Predict Antibody-Mediated Rejection Risk in Kidney Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31091373" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
